SK51199A3 - Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use - Google Patents

Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use Download PDF

Info

Publication number
SK51199A3
SK51199A3 SK511-99A SK51199A SK51199A3 SK 51199 A3 SK51199 A3 SK 51199A3 SK 51199 A SK51199 A SK 51199A SK 51199 A3 SK51199 A3 SK 51199A3
Authority
SK
Slovakia
Prior art keywords
gax
protein
polypeptide
dna
fragment
Prior art date
Application number
SK511-99A
Other languages
English (en)
Slovak (sk)
Inventor
Didier Branellec
Alain Fournier
Abderrahim Mahfoudi
Christophe Marcireau
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of SK51199A3 publication Critical patent/SK51199A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/80—Nucleic acid, e.g. DNA or RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK511-99A 1996-10-18 1997-10-16 Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use SK51199A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9612730A FR2754822B1 (fr) 1996-10-18 1996-10-18 Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
PCT/FR1997/001850 WO1998017686A1 (fr) 1996-10-18 1997-10-16 Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations

Publications (1)

Publication Number Publication Date
SK51199A3 true SK51199A3 (en) 2000-04-10

Family

ID=9496803

Family Applications (1)

Application Number Title Priority Date Filing Date
SK511-99A SK51199A3 (en) 1996-10-18 1997-10-16 Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use

Country Status (22)

Country Link
US (1) US6121005A (ru)
EP (1) EP0941243A1 (ru)
JP (1) JP2001503615A (ru)
KR (1) KR20000049249A (ru)
CN (1) CN1237980A (ru)
AP (1) AP9901510A0 (ru)
AU (1) AU741586B2 (ru)
BG (1) BG63548B1 (ru)
BR (1) BR9711947A (ru)
CA (1) CA2268045A1 (ru)
CZ (1) CZ131899A3 (ru)
EA (1) EA003694B1 (ru)
FR (1) FR2754822B1 (ru)
HU (1) HUP9903956A3 (ru)
IL (1) IL129478A0 (ru)
NO (1) NO991830L (ru)
NZ (1) NZ335283A (ru)
OA (1) OA11034A (ru)
PL (1) PL332874A1 (ru)
SK (1) SK51199A3 (ru)
WO (1) WO1998017686A1 (ru)
ZA (1) ZA979390B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001289652A1 (en) * 2000-06-28 2002-01-08 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
JP2013522169A (ja) * 2010-02-24 2013-06-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 炎症および好中球減少症の処置のための化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5554181A (en) * 1994-05-04 1996-09-10 Regents Of The University Of Minnesota Stent
GB9422175D0 (en) * 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
FR2740344B1 (fr) * 1995-10-31 1997-11-21 Rhone Poulenc Rorer Sa Application de la proteine gax au traitement de cancers

Also Published As

Publication number Publication date
BG103342A (en) 2000-05-31
FR2754822B1 (fr) 1998-11-27
EP0941243A1 (fr) 1999-09-15
EA199900387A1 (ru) 1999-10-28
JP2001503615A (ja) 2001-03-21
NO991830D0 (no) 1999-04-16
FR2754822A1 (fr) 1998-04-24
KR20000049249A (ko) 2000-07-25
US6121005A (en) 2000-09-19
AP9901510A0 (en) 1999-06-30
BR9711947A (pt) 1999-08-24
CA2268045A1 (fr) 1998-04-30
HUP9903956A3 (en) 2002-01-28
OA11034A (fr) 2003-03-06
AU4871397A (en) 1998-05-15
PL332874A1 (en) 1999-10-25
HUP9903956A2 (hu) 2000-03-28
IL129478A0 (en) 2000-02-29
CZ131899A3 (cs) 1999-07-14
CN1237980A (zh) 1999-12-08
AU741586B2 (en) 2001-12-06
NZ335283A (en) 2001-02-23
EA003694B1 (ru) 2003-08-28
NO991830L (no) 1999-06-16
BG63548B1 (bg) 2002-04-30
ZA979390B (en) 1998-05-12
WO1998017686A1 (fr) 1998-04-30

Similar Documents

Publication Publication Date Title
CA2340328C (en) Stable hypoxia inducible factor-1 alpha and method of use
CZ308897A3 (cs) Virové vektory a jejich použití pro léčení hyperprofilerativních nemocí, zejména restenosy
US6933373B2 (en) P53 protein variants and therapeutic uses thereof
EP0938553B1 (en) Dna encoding dp-75 and a process for its use
TW496873B (en) Bispecific chimeric molecule, nucleic acid sequence thereof, and in vitro expression system containing the same
SK51199A3 (en) Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use
EP0846761A1 (en) A novel transcription factor expressed in cycling cells, nucleic acid molecules encoding said transcription factor and its promoter region and uses thereof
US6544948B1 (en) ΔP62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer
WO1998019686A1 (en) Therapeutic methods for vascular injury
WO1998019686A9 (en) Therapeutic methods for vascular injury
MXPA99003470A (en) Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use
JP2002509433A (ja) 心筋および骨格筋に特異的な核酸、ならびにその製造方法および使用
WO2001018036A2 (en) Methods and reagents for regulating gene expression
JPH0866192A (ja) ヒトｓ−Ｍｙｃ様ポリペプチド及びそれをコードする遺伝子
Clair The dual specificity phosphatase Cdc25C is transcriptionally repressed by the tumor suppressor protein p53
MXPA97006928A (es) Sistema de expresion condicional
EP1401482A1 (en) Yin yang-1
MXPA97008877A (en) P62, its variants, the nucleic acid sequences that code them, and its use in anti-cancer gene therapy
AU2002308413A1 (en) Yin yang 1